Commentary: The Corrona-National Psoriasis Foundation Psoriasis Registry : A new collaborative approach for postapproval registries - 13/01/18
Doi : 10.1016/j.jaad.2017.10.011
Bruce Strober, MD, PhD ⁎ 
University of Connecticut Health Center, Farmington, Connecticut
Probity Medical Research, Waterloo, Canada
∗Reprint requests: Bruce Strober, MD, PhD, 21 South Rd, 2nd floor, Farmington, CT 06032.21 South Rd, 2nd floorFarmingtonCT06032
Key words : biologic therapy, effectiveness, psoriasis, real-world, registry, safety, systemic therapy
Abbreviations used : IL, NPF, RA
Le texte complet de cet article est disponible en PDF.
| Funding sources: Corrona Psoriasis Registry is sponsored by Corrona LLC and is funded by AbbVie, Boehringer Ingelheim, Celgene, Valeant, Merck, Eli Lilly and Company, and Novartis Pharmaceutical Corporation. During the last 2 years, Corrona LLC has been supported by AbbVie, Amgen, AstraZeneca, Bristol-Myers Squibb, Crescendo, Eli Lilly and Company, Genentech, GlaxoSmithKline, Horizon Pharma USA, Janssen, Momenta Pharmaceuticals, Novartis, Pfizer, Roche, and UCB through contracted subscriptions. |
|
| Conflicts of interest: Dr Strober received honoraria for serving as consultant and on the advisory boards for AbbVie, Amgen, Astra Zeneca, Celgene, Dermira, Janssen, Leo, Eli Lilly, Cutanea-Maruho, Medac, Novartis, Pfizer, Sun Pharma, Boehringer Ingelheim, UCB, and Valeant; was an investigator for AbbVie, Amgen, Boehringer Ingelheim, GlaxoSmithKline, Novartis, Lilly, Janssen, Merck, Sun Pharma, and Celgene (payments for which were received by the University of Connecticut and not Dr Strober); received consulting fees for serving as scientific director for Corrona Psoriasis Registry; and received grant support for the University of Connecticut for a fellowship program and not Dr Strober from AbbVie and Janssen. |
|
| IRB Statement: All participating investigators were required to obtain full board approval for conducting research involving human subjects. Sponsor approval and continuing review was obtained through a central institution review board (IRB; IntegReview, Corrona-PSO-500). For academic investigative sites that did not receive a waiver to use the central IRB, full board approval was obtained from the respective governing IRBs and documentation of approval was submitted to the sponsor before initiating any study procedures. All registry subjects were required to provide written, informed consent before participating. |
© 2017
American Academy of Dermatology, Inc.. Publié par Elsevier Masson SAS. Tous droits réservés.
Vol 78 - N° 2
P. 333-335 - février 2018 Retour au numéro
Article précédent
- Characterization of disease burden, comorbidities, and treatment use in a large, US-based cohort: Results from the Corrona Psoriasis Registry
- Bruce Strober, Chitra Karki, Marc Mason, Ning Guo, Stacey H. Holmgren, Jeffrey D. Greenberg, Mark Lebwohl
- Sleep disturbance in children with moderate/severe atopic dermatitis: A case-control study
- Anna B. Fishbein, Kelly Mueller, Lacey Kruse, Peter Boor, Stephen Sheldon, Phyllis Zee, Amy S. Paller
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?